A Cell Culture–Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals by Ehrlich, Hartmut J. et al.
MAJOR ARTICLE
A Cell Culture–Derived Inﬂuenza Vaccine
Provides Consistent Protection Against Infection
and Reduces the Duration and Severity of
Disease in Infected Individuals
Hartmut J. Ehrlich,1 Julia Singer,1 Gregory Berezuk,2 Sandor Fritsch,1 Gerald Aichinger,3 Mary Kate Hart,4
Wael El-Amin,4 Daniel Portsmouth,5 Otfried Kistner,5 and P. Noel Barrett5
1Global R&D, Baxter BioScience, Vienna, Austria; 2Vaccine R&D, Baxter BioScience, Beltsville, Maryland; 3Vaccine R&D, Baxter BioScience, Vienna,
Austria; 4DynPort Vaccine Company, Frederick, Maryland; and 5Vaccine R&D, Baxter BioScience, Orth/Donau, Austria
Background. Current knowledge of the consistency of protection induced by seasonal inﬂuenza vaccines
over the duration of a full inﬂuenza season is limited, and little is known about the clinical course of disease in
individuals who become infected despite vaccination.
Methods. Data from a randomized double-blind placebo-controlled clinical trial undertaken in healthy
young adults in the 2008–2009 inﬂuenza season were used to investigate the weekly cumulative efﬁcacy of a Vero
cell culture–derived inﬂuenza vaccine. In addition, the duration and severity of disease in vaccine and placebo
recipients with cell culture–conﬁrmed inﬂuenza infection were compared.
Results. Vaccine efﬁcacy against matching strains was consistently high (73%–82%) throughout the study,
including the entire period of the inﬂuenza season during which inﬂuenza activity was above the epidemic
threshold. Vaccine efﬁcacy was also consistent (68%–83%) when calculated for all strains, irrespective of antigenic
match. Vaccination also ameliorated disease symptoms when infection was not prevented. Bivariate analysis of
duration and severity showed a signiﬁcant amelioration of myalgia (P 5 .003), headache (P 5 .025), and fatigue
(P 5 .013) in infected vaccinated subjects compared with placebo. Cough (P 5 .143) and oropharyngeal pain
(P 5 .083) were also reduced in infected vaccinated subjects.
Conclusions. A Vero cell culture–derived inﬂuenza vaccine provides consistently high levels of protection
against cell culture–conﬁrmed infection by seasonal inﬂuenza virus and signiﬁcantly reduces the duration and
severity of disease in those individuals in which infection is not prevented.
Clinical Trials Registration. ClinicalTrials.gov NCT00566345.
Annual immunization is the most effective in-
tervention to prevent disease resulting from infection
with seasonal inﬂuenza virus. The efﬁcacy of cur-
rently licensed trivalent seasonal inﬂuenza vaccines
(TIVs) in preventing laboratory-conﬁrmed inﬂuenza
infection has been demonstrated in a number of recent
placebo-controlled trials [1–5]. However, inﬂuenza
vaccine efﬁcacy studies have rarely addressed the
consistency of vaccine-induced protection; vaccine
efﬁcacy is generally reported as a point estimate for
the entire study period, irrespective of the chronological
distribution of breakthrough infections. Considering
that a single vaccination is intended to protect against
seasonal inﬂuenza epidemics that may occur from early
autumn until late spring, further evaluation of the
stability of the protection provided by seasonal in-
ﬂuenza vaccines is warranted.
Inﬂuenza vaccine efﬁcacy can be inﬂuenced by
a number of factors, including the extent to which
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antigenic similarity between circulating virus strains and
thoseincluded in the vaccine [6]; in clinical trials, laboratory-
conﬁrmed infections are reported in a proportion of subjects
despite vaccination. However, little is known about the clinical
course of disease in these individuals. Efﬁcacy studies that use
laboratory-conﬁrmed inﬂuenza infection as a clinical endpoint
seldom report the duration or severity of disease associated
with breakthrough infections. A reduction in inﬂuenzalike illness
( I L I )s y m p t o m si sf r e q u e n t l yu s e da sal e s ss t r i n g e n tc l i n i c a l
endpoint to demonstrate vaccine effectiveness, but, without lab-
oratory conﬁrmation, it is difﬁcult to infer a causal relationship
between vaccination, inﬂuenza infection, and disease status [7].
A recent phase III placebo-controlled trial demonstrated
a novel Vero cell culture–derived seasonal inﬂuenza vaccine
(VCIV) to be 78.5% efﬁcacious against cell culture–conﬁrmed
inﬂuenza infection (CCII) with antigenically matched virus
strains [1]. In the present study, we undertook additional analyses
of data from this trial to assess the consistency of vaccine efﬁcacy
over a complete inﬂuenza season and to investigate the potential
of the vaccine to ameliorate disease symptoms in individuals in
which infection is not prevented.
METHODS
Study Design and Objectives
A randomized, double-blind placebo-controlled phase III trial
investigating the efﬁcacy of a VCIV has been described else-
where [1]. This study was undertaken during the 2008–2009
Northern hemisphere inﬂuenza season at 36 centers
throughout the United States in healthy young adults aged
18–49 years. The primary studyobjective was to demonstrate the
efﬁcacy of VCIV in preventing CCII due to inﬂuenza virus that
was antigenically matched to 1 of the vaccine strains. Post hoc
analyses were performed to assess the consistency of vaccine
efﬁcacy and to determine the effect of vaccination on the
duration and severity of disease in infected individuals. The
Sterling Institutional Review Board, Atlanta, GA, approved the
study protocol and consent forms used in the study, which was
conducted in compliance with Good Clinical Practice guidelines
and the Declaration of Helsinki. The study employed a 4-member
independent Data Monitoring Committee. Individuals who
demonstrated an understanding of the study and provided written
informed consent were accepted as potential study volunteers.
Vaccination and ILI Follow-up
Subjects were equally randomized to receive an intramuscular
injection of 0.5 mL VCIV or placebo. VCIV is a trivalent split
vaccine that was formulated to contain 15 lgo fh e m a g g l u t i n i n
antigen from each of the vaccine strains A/Brisbane/59/2007
(A/H1N1), A/Uruguay/716/2007 (A/H3N2), and B/Florida/
4/2006. Vaccine viruses were egg-derived wild-type strains
provided by the National Institute for Biological Standards and
Control, Potters Bar, United Kingdom, which were subjected
to 3 passages in Vero cell culture prior to vaccine production.
Sequence analysis of the production viruses showed that typical
mutations resulting from egg growth were retained following
culture in Vero cells. Placebo was phosphate-buffered saline.
From 3 weeks postvaccination, subjects were instructed to
return to the clinic for an ILI visit within 48 hours of onset
of symptoms should they experience fever with cough, sore
throat, muscle ache, headache, fatigue, nausea, or bloodshot
eyes, or if they should experience any 2 of the listed symptoms
in the absence of fever. At every ILI visit, nasopharyngeal swabs
were obtained for culturing and typing of viruses.
Assessment of Disease Severity and Duration
ILI duration and severity data were obtained by post hoc review
of subjects’ case report forms. Disease severity was investigator-
assessed and classiﬁed as being mild, moderate, or severe.
Symptoms that caused transient discomfort, which do not sig-
niﬁcantly interfere with normal function, and which resolve
spontaneously or which may require minimal therapeutic in-
tervention, were classiﬁed as mild. Symptoms that caused lim-
ited impairment of function, which could require therapeutic
intervention but which caused no sequelae, were classiﬁed as
moderate. Symptoms that resulted in marked impairment of
function, which could lead to a temporary inability to resume
normal life, and which produced sequelae that required pro-
longed therapeutic intervention, were classiﬁed as severe.
Laboratory Confirmation and Antigenic Typing of Influenza
Viruses
Virus specimens collected using nasopharyngeal swabs at ILI
visitswereshipped toBio AnalyticalResearch Corporation,Lake
Success, New York, for culture using traditional cell culture
and Rapid R-Mix (Diagnostic Hybrids, Athens, Ohio) and virus
typing via real-time polymerase chain reaction. The antigenic
relatedness of virus isolates to vaccine strains was determined
by hemagglutination inhibition analysis at the laboratory of
the Inﬂuenza Division, National Center for Immunization and
Respiratory Diseases, Centers for Disease Control and Preven-
tion (CDC). Genetic sequencing was done by GENEWIZ Inc,
South Plainﬁeld, New Jersey. Assessment of the genetic lineage
of the B strains was performed at the Institute of Virology,
Medical University of Vienna, Austria.
Statistical Analyses
Calculation of the cumulative weekly vaccine efﬁcacy included
all randomly assigned and immunized participants who stayed in
the study for at least 21 days after vaccination. Cumulative vaccine
efﬁcacy (VE) was computed by the formula VE 5 (1 2 RR) 3
100, where RR is the ratio of inﬂuenza infection risk in the VCIV
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conﬁdence interval (CI) of the RR was computed by the
method proposed by Miettinen and Nurminen [8].
Analysis of the duration and severity of ILI symptoms was
performed on all subjects with CCII. Subjects were analyzed
as randomized; there were no randomization errors in this
subset. All the Medical Dictionary for Regulatory Activities
(MedDRA) preferred terms of adverse events (ILI symptoms)
associated with inﬂuenza infection occurring within 3 days
from the date of swab collection were listed. If a symptom oc-
curred more than once in any subject, durations were added,
whereas severity was considered to be the maximum of the se-
verity scores. Symptoms with an incidence of ,10% were not
included in further analyses. To compare the joint distribution
of duration and severity between the 2 treatment groups,
a bivariate nonparametric permutation-based method (POSET
test [9]) was applied, preceded by a partial ordering procedure
on the pairs of data (severity, duration) in order to assign ranks
to each pair. No adjustments were made for multiplicity. For
each P value, 40 000 permutations were generated in order to
obtain a standard error of around 0.001.
RESULTS
Study Participants
The ﬂow of participants through the study is shown in Figure 1.
All study subjects were vaccinated between 1 and 15 December
2008. The baseline characteristics of participants who received
either VCIV or placebo is shown in Table 1. A total of 7243
participants received either VCIV (3623) or placebo (3620). The
VCIV and placebo groups were evenly balanced by age and
sex. The age range in both groups was 18–49 years, and the
median age was 31 and 30 years for the VCIV and placebo
groups, respectively. Analysis of swab specimens obtained at
Figure 1. Flow of participants through the study. Abbreviation: VCIV, Vero cell culture–derived influenza vaccine.
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inﬂuenza infections were recorded for specimens collected
after the week ending 9 May.
Consistency of Vaccine Efficacy Throughout an Entire Influenza
Season
To investigate the consistency of vaccine efﬁcacy on a week-
by-week basis over the duration of the inﬂuenza season, the
cumulative frequency of infections occurring in subjects
receiving either vaccine or placebo were analyzed. Up to the
week ending 17 January 2009, only 7 subjects reporting with
ILI were shown to be infected with inﬂuenza virus. Six of these
subjects had received placebo, with only a single vaccine
recipient becoming infected during this period. However, due
to the low number of infections, no statistical analysis of
the consistency of vaccine efﬁcacy could be carried out until
the week ending 24 January 2009.
Figure 2 shows the cumulative efﬁcacy of VCIV in pre-
venting CCII from the week ending 24 January to the week
ending 9 May 2009. These data show that vaccine efﬁcacy is
consistently high, including for the duration of the entire
period from the end of January through mid-March during
which inﬂuenza activity was above the epidemic threshold
[10]. The weekly cumulative point estimate for vaccine efﬁ-
cacy was 71%–82% against cell culture–conﬁrmed infection
with antigenically matched A/H1N1 strains (Figure 2A),
73%–82% for cell culture–conﬁrmed infections with all
antigenically matched strains (Figure 2B), and 68%–83% for
all cell culture–conﬁrmed infections, irrespective of antigenic
similarity to the vaccine strains (Figure 2C). The wider
95% CIs for the point estimates of vaccine efﬁcacy during the
ﬁrst weeks of the observation period are a consequence of the
low cumulative number of infections during this period (a total
of only 14 infections up to the week ending 31 January),
reﬂecting the fact that the seasonal inﬂuenza activity in the
United States remained below the national baseline until the
end of January and did not peak until mid-February [10].
Vaccine efﬁcacy was at least as high in the later stages of the
study compared with earlier stages; the weekly cumulative vac-
cine efﬁcacy from the beginning of March onward was .78%
for antigenically matched A/H1N1 strains, .77% for all anti-
genically matched strains, and .70% for all strains, irrespective
of antigenic match. The consistency of vaccine efﬁcacy over time
was also investigated by dividing the study into 2 periods and
analyzing vaccine efﬁcacy in the ﬁrst 3 months of the study
compared with the period thereafter. In the ﬁrst period, 10 of
3619VCIVrecipients had antigenically matchedCCIIcompared
with 40 of 3617 placebo recipients, such that vaccine efﬁcacy
was estimated to be 75.0% (95% CI, 50.8%–87.3%). In the
second period, 3 of 3532 VCIV recipients had antigenically
matched CCII compared with 20 of 3530 placebo recipients,
resulting in vaccine efﬁcacy of 85.0% (95% CI, 52.8%–95.2%).
This analysis demonstrates that vaccine efﬁcacy was similar
during both periods.
Duration and Severity of ILI Symptoms in VCIV and Placebo
Recipients With Cell Culture–Confirmed Influenza Infection
Despite the high efﬁcacy of VCIV in preventing inﬂuenza in-
fection, over the duration of the study a total of 21 vaccinated
individuals were nevertheless infected with inﬂuenza virus as
determined by CCII. To investigate the potential of vaccina-
tion to ameliorate inﬂuenza disease symptoms in subjects in
which infection is not prevented, we compared the severity
and duration of ILI symptoms in all placebo and VCIV recipients
with CCII. For the majority of symptoms, VCIV recipients had
a reduced proportion of cases rated moderate or severe and
a reduced proportion of cases of longer duration (Figure 3).
VCIV recipients experienced no severe cough, oropharyngeal
pain, myalgia, headache, or nausea, and only single cases of
severe pyrexia or fatigue. The mean and median duration of
all ILI symptoms were reduced for VCIV recipients with the
exception of nausea, and the mean severity score of all symp-
toms was reduced for all VCIV recipients with the exception
of pyrexia (Table 2). Bivariate statistical analyses of the joint
beneﬁt of reduction in disease severity and duration show that
this is signiﬁcant for myalgia (P 5 .003), headache (P 5 .025),
and fatigue (P 5 .013). There were also reductions in the du-
ration and severity of cough (P 5 .143) and oropharyngeal
pain (P 5 .083) for VCIV recipients, although these are not
statistically signiﬁcant.
DISCUSSION
We investigated the consistency of protection induced by
a novel Vero cell culture–derived seasonal inﬂuenza vaccine
in the United States in 2008–2009. Only low levels of in-
ﬂuenza activity were detected up until mid-January 2009, but
activity increased in mid-January, peaking in mid-February,
Table 1. Baseline Characteristics of Participants Receiving Vero
Cell Culture–Derived Influenza Vaccine or Placebo
Characteristics
VCIV
(n 5 3623)
Placebo
(n 5 3620)
Overall
(n 5 7243)
Male, No. (%) 1823 (25.2) 1865 (25.7) 3688 (50.9)
Female,
No. (%)
1800 (24.9) 1755 (24.2) 3555 (49.1)
Age, years,
mean (SD)
[median]
32.2 (9.7) [31.0] 32.1 (9.7) [30.0] 32.1 (9.7) [31.0]
Age range,
years
18–49 18–49 18–49
Abbreviations: SD, standard deviation; VCIV, Vero cell culture–derived inﬂuenza
vaccine.
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vaccine was consistently highly efﬁcacious in preventing lab-
oratory-conﬁrmed inﬂuenza infection over this entire period
(Figure 2). Importantly, vaccine efﬁcacy did not wane as the
inﬂuenza season progressed; the weekly cumulative vaccine
efﬁcacy from the beginning of March onward was .78%
for antigenically matched A/H1N1 strains, .77% for all
antigenically matched strains, and .70% for all strains,
irrespective of antigenic match. This is also demonstrated by
the similarly high estimates of vaccine efﬁcacy for antigenically
matched strains in the ﬁrst 3 months of the study (75.0%)
compared with the period thereafter (85.0%). Because subjects
were vaccinated in December, our study does not allow us to
be certain that vaccine efﬁcacy would be maintained at equally
high levels to the end of an inﬂuenza season if vaccination
were to be initiated at an earlier time point, as recommended
by the CDC [11]. However, as there was no indication of a re-
duction in vaccine efﬁcacy up to 5 months after vaccination,
it seems likely that earlier vaccination would also provide
season-long protection.
Other studies assessing the longevity or consistency of vac-
cine efﬁcacy against infection with seasonal inﬂuenza virus
are limited. Historically, monovalent vaccines were reported to
provide extended protection against the Hong Kong [12, 13]
and Russian pandemic strain viruses [14]. More recent studies
have reported a trivalent live-attenuated inﬂuenza vaccine (LAIV)
to provide stable levels of protection against CCII for up to
12 months in children [15], and, in comparative studies, LAIV
was relatively more efﬁcacious than TIV in preventing CCII
.4–8 months postvaccination compared to 0–4 months post-
vaccination [16]. To our knowledge, the consistency of the
protective efﬁcacy of modern split or subunit TIVs compared
with placebo has not previously been demonstrated in any
population.
The cumulative vaccine efﬁcacy estimates and efﬁcacy up to
or after 3 months reported here for the Vero-derived vaccine
are similar to those determined for the entire study period,
where vaccine efﬁcacy was estimated to be 79% for antigenically
matched A/H1N1 strains, 78.5% for all matched strains, and
71.5% for all strains, irrespective of antigenic match [1]. It is
difﬁcult to compare absolute vaccine efﬁcacy between inde-
pendent studies due to a number of factors that cause hetero-
geneity between different studies, such as differences in virus
strains, attack rate of circulating viruses, and clinical endpoints
used; however, these efﬁcacy estimates are in the upper range
of those reported in other recent studies of seasonal inﬂuenza
vaccines [2–5, 17, 18] and similar to or higher than those re-
ported in recent meta-analyses of TIV efﬁcacy [19, 20].
A proportion of individuals were infected with inﬂuenza
virus despite vaccination. However, our results demonstrate
that the beneﬁt of vaccination extends beyond the prevention
of infection, because the majority of ILI symptoms in sub-
jects with CCII were both milder and of shorter duration in
vaccine recipients compared with placebo recipients (Figure 3).
In the cases of myalgia (P 5 .003), headache (P 5 .025), and
fatigue (P 5 .013), the joint reduction in disease duration and
severity was statistically signiﬁcant (Table 2). The demonstration
of statistical signiﬁcance of VCIV in amelioration of disease is
noteworthy in the context of the high efﬁcacy of the vaccine in
preventing inﬂuenza infection. This resulted in a small sample
Figure 2. Weekly cumulative vaccine efficacy against cell culture–
confirmed influenza infection. Vaccine efficacy could be calculated from
24 January 2009, 6 weeks after vaccination of the last subject on
15 December. Analysis of specimens from influenzalike illness visits
continued until 15 May; the last laboratory-confirmed influenza infection
was recorded in the week ending 9 May 2009.
950 d CID 2012:54 (1 April) d Ehrlich et alFigure 3. Amelioration of disease symptoms in subjects with cell culture–confirmed influenza infection. Symptoms are rated as severe (red), moderate
(orange), or mild (green).
aFour placebo recipients had cough for .20 days. Three were rated as moderate (31, 35, and 51 days duration), and 1 was rated
as severe (22 days duration).
bOne recipient of Vero cell culture–derived influenza vaccine had oropharyngeal pain for 31 days, rated moderate.
Abbreviation: VCIV, Vero cell culture–derived influenza vaccine.
VCIV Consistency and Disease Amelioration d CID 2012:54 (1 April) d 951size for infected VCIV recipients and, consequently, a lower
power of analysis, such that a larger effect is necessary to
demonstrate statistical signiﬁcance of disease amelioration than
would be the case for a less efﬁcacious vaccine. Amelioration
of cough (P 5 .143) and oropharyngeal pain (P 5 .083) was
also observed. The reduction in the severity and duration of
these symptoms may also be clinically relevant, although the
small sample size precluded the calculation of a statistically
signiﬁcant beneﬁt.
Previous investigations into the potential of inﬂuenza
vaccines to ameliorate disease in subjects with laboratory-
conﬁrmed inﬂuenza infection have been limited to a restricted
selection of ILI symptoms, and few statistically signiﬁcant re-
ductions in the severity or duration of disease symptoms have
been reported. A small number of studies have reported sig-
niﬁcant reductions in fever for TIV [21]o rL A I V[ 22]r e c i p i e n t s ,
or have shown a signiﬁcant beneﬁt of LAIV over TIV for
t h er e d u c t i o no ff e v e ri nc h i l d r e n[ 23]o ro l d e ra d u l t s[ 24].
Both TIV and LAIV have also been reported to reduce the rate
of acute otitis media (AOM) in children [25]; we did not in-
vestigate the occurrence of AOM because our study was of
young healthy adults, and AOM is not a common symptom of
inﬂuenza infection in this population. Prevention of infection
and disease in vaccinated individuals also has the potential
to beneﬁt nonvaccinated contacts by preventing or reducing
virus transmission. In this respect, the level of virus shedding
in individuals who were infected despite vaccination would
also be of interest. Our study did not include a quantitative
assay for detection of virus in nasopharyngeal specimens;
however, other studies have suggested that virus shedding
may be less effectively reduced in recipients of TIV compared
with recipients of LAIV [26–28].
The conclusions of our study are subject to the limitations
that are inherent to any post hoc analyses of study data. In
addition, because no study arm with an egg-derived vaccine was
included, we cannot make a direct comparison of vaccines
produced in Vero cell culture or using standard technology.
Other limitations are that due to the nature of the 2008–2009
inﬂuenza season, data are primarily for the A/H1N1 strain and
only for adults aged 18–49 years because vaccination was rec-
ommended for all other populations in the United States at
the time of the study. However, the potential clinical and so-
cioeconomic beneﬁts of vaccination in younger adults are also
substantial [29–31], as reﬂected in the global drive to increase
vaccine coverage beyond traditional high-risk groups. In the
United States, annual vaccination is now recommended for all
individuals above the age of 6 months [32], and it is the aim of
the US Healthy People 2020 goals to achieve 80%–90% vaccine
coverage [33]. Improvements in inﬂuenza vaccine supply may
be required to achieve these goals, and the availability of
Table 2. Bivariate Analysis of the Severity and Duration of Influenzalike Illness Symptoms Among Subjects With Cell Culture–
Confirmed Influenza Infection
No. (%) of Subjects With Symptoms
Symptoms Total Mild Moderate Severe
Mean Severity
Score
a
Duration, Days,
Mean (Median) P Value
b
VCIV (n 5 21)
Pyrexia 12 (57) 5 (23.8) 6 (28.6) 1 (4.8) 1.7 3.6 (3.0) .491
Cough 15 (71) 9 (42.9) 6 (28.6) 0 1.4 8.8 (7.0) .143
Oropharyngeal pain 16 (76) 10 (47.6) 6 (28.6) 0 1.4 7.4 (5.0) .083
Myalgia 13 (62) 8 (38.1) 5 (23.8) 0 1.4 4.2 (3.0) .003
Headache 11 (52) 9 (42.9) 2 (9.5) 0 1.2 5.6 (5.0) .025
Fatigue 12 (57) 8 (38.1) 3 (14.3) 1 (4.8) 1.4 4.9 (3.5) .013
Nausea 8 (38) 5 (23.8) 3 (14.3) 0 1.4 6.9 (6.0) .479
Placebo (n 5 74)
Pyrexia 48 (65) 26 (35.1) 17 (23.0) 5 (6.8) 1.6 4.4 (3.5) .
Cough 63 (85) 28 (37.8) 30 (40.5) 5 (6.8) 1.6 10.0 (8.0) .
Oropharyngeal pain 43 (58) 21 (28.4) 19 (25.7) 3 (4.1) 1.6 8.1 (7.0) .
Myalgia 51 (69) 20 (27.0) 29 (39.2) 2 (2.7) 1.6 7.8 (7.0) .
Headache 45 (61) 24 (32.4) 17 (23.0) 4 (5.4) 1.6 7.1 (6.0) .
Fatigue 42 (57) 19 (25.7) 21 (28.4) 2 (2.7) 1.6 7.4 (6.0) .
Nausea 21 (28) 11 (14.9) 10 (13.5) 0 1.5 5.1 (5.0) .
Abbreviations: ILI, inﬂuenzalike illness; VCIV, Vero cell culture–derived inﬂuenza vaccine.
a Symptoms rated as mild were given a score of 1, moderate symptoms a score of 2, and severe symptoms a score of 3.
b P value (POSET test) of the reduction in severity and duration of symptoms in VCIV recipients compared with placebo recipients.
952 d CID 2012:54 (1 April) d Ehrlich et almodern, robust, and ﬂexible manufacturing technologies will
facilitate this process [34, 35]. The present study makes an im-
portant contribution to a growing body of evidence supporting
the use of cell culture technology for vaccine manufacture.
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